Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Hausmaninger, H; Lehnert, M; Steger, G; Sevelda, P; Tschurtschenthaler, G; Hehenwarter, W; Fridrik, M; Samonigg, H; Schiller, L; Manfreda, D.
Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.
Eur J Cancer. 1995; 31A(13-14):2169-2173
Doi: 10.1016%2F0959-8049%2895%2900489-0
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Samonigg Hellmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The purpose of this study was to compare the activity and toxicity of epirubicin-vindesine (EV) with mitoxantrone-vindesine (MV) in patients with metastatic breast cancer. A total of 295 patients was randomly allocated to treatment with vindesine 3 mg/m2 combined with either epirubicin 40 mg/m2 or mitoxantrone 10 mg/m2. All drugs were given by intravenous push, treatment cycles were repeated at 3-4 week intervals. 255 patients were available for response, and 283 for toxicity. EV and MV yielded similar objective response rates (34 and 26%, respectively), response durations, times to progression and survival. Median time to remission was 1.8 and 3.1 months (P = 0.006) with EV and MV, respectively. In patients with visceral metastases, response rate was higher with EV than MV (40 versus 23%; P = 0.03). Patients receiving MV had less nausea/vomiting (P = 0.007) and alopecia (P = < 0.001) of WHO grade > or = 2. Bone marrow, cardiac and other toxicities were mild with both treatments. The observed differences in activity and toxicity between the two regimens appear to have clinical relevance. EV proved to be more active in visceral disease and to be able to induce remissions more rapidly. Accordingly, patients with visceral metastases or severe tumour-related symptoms may benefit from epirubicin-based treatment. Subjective toxicities, i.e. nausea/vomiting and alopecia, were less frequent and severe with MV. Thus, MV may prove useful in patients with more indolent disease and appears to warrant phase III evaluation in such patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Bone Neoplasms - drug therapy
- Breast Neoplasms - drug therapy
- Digestive System Neoplasms - drug therapy
- Epirubicin - administration and dosage
- Female - administration and dosage
- Humans - administration and dosage
- Middle Aged - administration and dosage
- Mitoxantrone - administration and dosage
- Remission Induction - administration and dosage
- Soft Tissue Neoplasms - drug therapy
- Survival Analysis - drug therapy
- Vindesine - administration and dosage
- Find related publications in this database (Keywords)
- Metastatic Breast Cancer
- Epirubicin
- Mitoxantrone
- Vindesine